Quick Summary
Tecvayli 30mg Injection
Last updated on 12 Jun 2026 | 10:07 AM (IST)
₹66946
MRP: ₹74384
(You Save ₹7438)
1 VIAL(s) OF 3ML
Tecvayli 30mg Injection
Salt Composition
TECLISTAMABMarketer
JOHNSON & JOHNSON PVT LTD
Prepaid Only. Non-Returnable.
10% OFF
₹66946
MRP: ₹74,384.00
Inclusive of all taxes
10% Off
Salt Composition
TECLISTAMABMarketer
JOHNSON & JOHNSON PVT LTD
Prepaid Only. Non-Returnable.
Dispatch: Today
Order In: 0h 0m 0s
0h 0m 0s
Order before timer ends to ensure your medicine is dispatched at...
Introduction to Tecvayli 30mg Injection
Tecvayli 30mg Injection contains the active substance Teclistamab. It is an anticancer medication classified as a bispecific monoclonal antibody. Tecvayli 30mg Injection is used for the treatment of adult patients with relapsed or refractory multiple myeloma, a type of cancer affecting plasma cells in the bone marrow, who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Tecvayli works by targeting and binding to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognise and destroy the BCMA-expressing myeloma cells.
Inform your doctor before starting treatment with Tecvayli 30mg Injection, as it may lead to serious side effects such as cytokine release syndrome (CRS), neurotoxicities, and infections. Regular monitoring and prompt management of these conditions are crucial during therapy. Make sure to inform your physician of all the medicines you are taking before starting treatment with Tecvayli 30mg Injection. Report any symptoms such as difficulty breathing, cough, fever, chest pain, weakness, or seizures to your doctor.
Uses of Tecvayli 30mg Injection
To treat adult patients with relapsed or refractory multiple myeloma (a type of cancer affecting plasma cells in the bone marrow) who have previously received at least four lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
Therapeutic Effects of Tecvayli 30mg Injection
Tecvayli 30mg Injection works by targeting and binding specifically to both B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells. This dual binding activates T cells to recognise and destroy the BCMA-expressing myeloma cells, thereby inhibiting their growth and proliferation.
Interaction of Tecvayli 30mg Injection with other drugs
Inform your healthcare professional about all the medicines you take, including prescription medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products.
Certain medications interacting with Tecvayli 30mg Injection may reduce effectiveness by causing undesirable side effects.
More Information about Tecvayli 30mg Injection
- Store Tecvayli 30mg Injection in the refrigerator at 2°C to 8°C. Do not freeze.
- Keep out of sight and reach of children and pets.
- Store in the original container to protect from light.
- Monitor patients regularly for signs and symptoms of cytokine release syndrome (CRS) and neurological toxicities.
- Regular blood tests should be conducted to detect any abnormalities and other potential side effects, as directed by the healthcare provider.
How to consume Tecvayli 30mg Injection
A healthcare professional administers Tecvayli 30mg Injection via intravenous infusion. The infusion is given over a specified duration as per your doctor’s treatment schedule. Do not self-administer the injection or alter the infusion schedule without consulting your healthcare provider.
Safety Advice for Tecvayli 30mg Injection
Breast Feeding
Don’t breastfeed while taking Tecvayli 30mg Injection and for 5 months after your last dose because the drug may come through into your breast milk.
Alcohol
It is not known whether it is safe to use Tecvayli 30mg Injection while consuming alcohol. Consult the doctor before taking this medication.
Liver
You need to inform your doctor if you have any liver disorders before starting Tecvayli 30mg Injection. Tecvayli may cause hepatotoxicity. Your doctor may adjust the dose or delay treatment based on your liver function.
Lungs
Before starting treatment with Tecvayli 30mg Injection, talk to your doctor if you have any lung conditions.
Driving
Tecvayli 30mg Injection may affect your ability to drive or operate heavy machinery due to potential neurological toxicity. Consult your doctor before taking this medication.
Pregnancy
Tecvayli 30mg Injection is not safe for use during pregnancy because it can harm the developing baby.
Side Effects of Tecvayli 30mg Injection
Like all medications, Tecvayli 30mg Injection can cause side effects, although not everyone who takes it will experience them.
Common:
- Cytokine release syndrome (fever, chills, nausea, fatigue)
- Neurological symptoms (headache, dizziness)
- Fatigue
- Injection site reactions
Rare:
- Severe neurological symptoms (confusion, seizures)
- Difficulty breathing or swallowing
- Swelling of the face, lips, or tongue
- High fever
- Skin rash or severe skin reactions
- Rapid heartbeat
Word of Advice
If you are undergoing any laboratory tests, inform your doctor that you are receiving a Tecvayli 30mg Injection. This medication may affect your laboratory results or the interpretation of certain tests.
Tecvayli may also cause neurological symptoms. Your doctor may recommend monitoring for signs such as confusion or dizziness. Please report any new symptoms or changes in your condition to your doctor without delay.
FAQs about Tecvayli 30mg Injection
Q1.
What are the doses for TECVAYLI?
Tecvayli (teclistamab) is available as a 30 mg/mL solution for intravenous infusion. The typical dosing involves an initial infusion of 1.5 mg/kg, followed by maintenance infusions of 1.5 mg/kg every two weeks. Always follow the specific dosing schedule advised by your healthcare provider.
Q2.
Is Tecvayli 30mg Injection chemotherapy?
No, Tecvayli 30mg Injection is not a type of chemotherapy. While both Tecvayli and chemotherapy drugs are used to treat multiple myeloma, they work differently. Tecvayli is a monoclonal antibody that targets specific proteins on cancer cells, whereas chemotherapy drugs generally work by killing rapidly dividing cells.
Q3.
When was Tecvayli 30mg Injection approved?
Tecvayli 30mg Injection was approved by the U.S. Food and Drug Administration (FDA) on October 18, 2022.
Q4.
Is TECVAYLI a hazardous drug?
Yes, Tecvayli (teclistamab) is considered a hazardous drug. It can cause serious side effects, such as cytokine release syndrome and neurological toxicities, which require careful handling and administration. Healthcare professionals should follow proper safety protocols when administering and handling this medication.
Fact Box of Tecvayli 30mg Injection
| Molecule name: Teclistamab | Pharmacological class : Bispecific monoclonal antibody
|
| Therapeutic class: Monoclonal antibody | Indications: To treat adult patients with relapsed or refractory multiple myeloma |
References
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
Did you find this information helpful?
Author Details
Written By
Dr. Deva Prasath S.
Pharm D
Reviewed By
Dr. Tejashwin Adiga
MBBS
Last updated : 12 Jun 2026 | 10:07 AM (IST)
Want to know more?
Read Our Editorial Policy
